Literature DB >> 15712099

Quinolones for treatment of nosocomial pneumonia: a meta-analysis.

Andrew F Shorr1, Gregory B Susla, Marin H Kollef.   

Abstract

Although quinolones are often used to treat nosocomial pneumonia (NP), there have been few trials documenting their efficacy in treating NP. Given the growing use of quinolones and issues regarding resistance, we conducted a meta-analysis of all trials of quinolones for treatment of NP. We identified 5 randomized trials comparing quinolones with other agents used to treat NP. The studies varied in both quality and sample size and included a total of nearly 1200 subjects. Four of the 5 trials used ciprofloxacin, administered every 8 h, whereas the fifth used levofloxacin administered daily. In 3 trials, the comparator agent was imipenem-cilistatin, whereas, in 2 trials, ceftazadime was the comparator agent. The efficacy of quinolones and comparator antibiotics was similar, with a pooled odds ratio for clinical cure of 1.12 (95% confidence interval, 0.80-1.55). Neither microbiological eradication rates nor mortality rates varied on the basis of antimicrobial selection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712099     DOI: 10.1086/426191

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

1.  Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?

Authors:  Ping-Feng Wu; Yi-Tsung Lin; Fu-Der Wang; Tsuey-Ching Yang; Chang-Phone Fung
Journal:  Infection       Date:  2018-03-20       Impact factor: 3.553

Review 2.  Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.

Authors:  Marya D Zilberberg; Joyce Chen; Samir H Mody; Andrew M Ramsey; Andrew F Shorr
Journal:  BMC Pulm Med       Date:  2010-08-26       Impact factor: 3.317

3.  Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Konstantinos Z Vardakas; Ilias I Siempos; Alexandros Grammatikos; Zoe Athanassa; Ioanna P Korbila; Matthew E Falagas
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.